First-in-human phase I study of BEBT-109 in previously treated EGFR exon 20 insertion-mutated advanced non-small cell lung cancer
L Zeng, L Song, L Liu, F Wu, Q Xu, H Yan, S Lin… - Med, 2024 - cell.com
Background BEBT-109 is an oral pan-mutant-selective inhibitor of epidermal growth factor
receptor (EGFR) that demonstrated promising antitumor potency in preclinical models …
receptor (EGFR) that demonstrated promising antitumor potency in preclinical models …
Real world treatment patterns, healthcare resource use and costs in patients with advanced or metastatic non-small cell lung cancer by EGFR mutation type
Aims This study described treatment patterns, healthcare resource utilization (HRU) and
costs among advanced or metastatic non-small cell lung cancer (a/mNSCLC) patients with …
costs among advanced or metastatic non-small cell lung cancer (a/mNSCLC) patients with …
Efficacy of Mobocertinib and Amivantamab in Patients With Advanced Non–Small Cell Lung Cancer With EGFR Exon 20 Insertions Previously Treated With Platinum …
Introduction Exon 20 insertions (ex20ins) mutations of the EGFR gene account for 1% to 2%
of all non–small-cell lung cancers (NSCLCs). Targeted therapies have been developed to …
of all non–small-cell lung cancers (NSCLCs). Targeted therapies have been developed to …
Is There a Unicorn Among the Uncommon EGFR Mutations?
The uncommon EGFR mutations remain a perennial challenge to treat. They constitute a
heterogenous group of molecular alterations within exons 18 to 21, which include …
heterogenous group of molecular alterations within exons 18 to 21, which include …
[HTML][HTML] Isolation, identification and structural characterization of forced degradation products of mobocertinib using LC-MS/MS and NMR
S Mishra, A Chauhan, R Ramajayam - Results in Chemistry, 2024 - Elsevier
The main objective of this study is to develop and validate an LC-MS/MS stability-indicating
method for the isolation, identification, and characterization of forced degradation products …
method for the isolation, identification, and characterization of forced degradation products …
Characteristics, treatment patterns, and clinical outcomes in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertions
YT Liao, LC Wang, RL Sun, YC Yeh, HC Huang… - Journal of Cancer …, 2023 - Springer
Purpose Epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) are
associated with poor prognosis and resistance to traditional therapies in patients with non …
associated with poor prognosis and resistance to traditional therapies in patients with non …
[HTML][HTML] EGFR罕见突变非小细胞肺癌患者的临床病理特征及治疗效果
孙文佳， 岳君秋， 王满香 - 肿瘤防治研究, 2023 - html.rhhz.net
目的探讨表皮生长因子受体(EGFR) 基因罕见突变非小细胞肺癌(NSCLC)
患者的临床病理特征及治疗效果. 方法采用荧光定量PCR 法检测674 例NSCLC 中EGFR …
患者的临床病理特征及治疗效果. 方法采用荧光定量PCR 法检测674 例NSCLC 中EGFR …
[引用][C] Christos Chouaid. Lise Bosquet. Nicolas Girard. Anna Kron. Matthias Scheffler. Frank Griesinger. Martin Sebastian. Jose Trigo. Santiago Viteri. Craig Knott …
PMJ Wolf - Adv Ther, 2023
[PDF][PDF] Targeting EGFR Exon 20 Insertion-mutated Cancers–New Perspectives in Head and Neck Cancers–Lessons to Learn from Non-small Cell Carcinoma (NSCLC …
CC MIRESTEAN, RI IANCU, DT IANCU - Modern Medicine, 2022 - researchgate.net
Mutations in the tyrosine kinase (TKD) domain of the epidermal growth factor receptor
(EGFR) are involved in the unfavorable therapeutic response through resistance to targeted …
(EGFR) are involved in the unfavorable therapeutic response through resistance to targeted …
The frequency of EGFR gene mutations in a cohort of Romanian patients with non-small cell lung cancer and their association with PD-L1 expression level and ALK …
EA Cohn, O Csutak, E Tataru - Revista Romana de Medicina de …, 2024 - sciendo.com
Background The mortality rate linked to non-small cell lung cancer (NSCLC) has notably
decreased in recent years, primarily due to refined diagnostic techniques. This retrospective …
decreased in recent years, primarily due to refined diagnostic techniques. This retrospective …